AstraZeneca Says Breast Cancer Pill Fails in Key Study

AstraZeneca Plc’s breast cancer pill failed to delay disease progression more than the standard treatment in a late-stage trial, results that could dampen optimism around the medicine.

By Ashleigh Furlong and Madison Muller · Bloomberg

AstraZeneca Plc’s breast cancer pill failed to delay disease progression more than the standard treatment in a late-stage trial, results that could dampen optimism around the medicine.